Loading patent…
AssigneeK.D. Pharma Bexbach GmbH
InventorsTobias Hartmann, Marcus Otto Walter Grimm, Thomas Floss, Anke Wittmann
Estimating the term…
An application of omega-3 and/or omega-6 fatty acid(s) for the therapeutic treatment of the human or animal body in the case of an impaired sphingolipid metabolism, in particular in the case of impaired sphingolipid synthesis and/or excessive sphingolipid degradation. The agent is applied in the case of missing, reduced and/or defective formation of a sphingomyelin synthase enzyme in the body, in particular the enzyme sphingomyelin synthase 1 or the enzyme sphingomyelin synthase 2. The application has proved to be useful in the case of a defect of the sphingomyelin synthase 1 gene or of the sphingomyelin synthase 2 gene. The omega-3 and/or omega-6 fatty acid(s) preferably comprise(s) polyunsaturated omega-3 and/or omega-6 fatty acid(s), preferably EPA, DHA, DPA, ETA, 21:5n3 and/or SDA. A method for determining a cause of a disease in an animal or a human being and a device for carrying out the method are also provided.
A method for treating a human or animal having an impaired sphingolipid metabolism, the method comprising administering to the human or animal an effective amount of an omega-3 and/or omega-6 fatty add or an ester or a salt thereof, wherein the treatment is for Niemann-Pick disease, Tay-Sachs disease, Sandhoff disease, Tay-Sachs AB variant, Gaucher disease, Fabry disease, Krabbe disease, GM1 gangliosidosis, metachromatic leukodystrophy or fucosidosis.
Dependencies are inferred from the claim text.